Brought to you by 
Gilead and Novo Nordisk sign trial collaboration for NASH combo therapy
18 Mar 2021
Executive Summary
Gilead Sciences Inc. and Novo Nordisk AS signed a trial agreement to study a triple combination therapy for nonalcoholic steatohepatitis (NASH).
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Intra-Biotech Deal
- Trial Collaborations
- R&D (No Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Gilead and Novo Nordisk sign trial collaboration for NASH combo therapy
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice